SCHEDULE: Braeden Lichti, Northstrive Fund II LP Disclose 5.01% Bluejay Stake

Braeden Lichti and Northstrive Fund II LP have disclosed a combined 5.01% beneficial ownership stake in Bluejay Diagnostics, Inc. common stock.

Summary

• Braeden Lichti and Northstrive Fund II LP have filed a Schedule 13G, reporting beneficial ownership in Bluejay Diagnostics, Inc.
• Braeden Lichti beneficially owns 35,500 shares, representing 5.01% of the outstanding common stock.
• Northstrive Fund II LP beneficially owns 11,000 shares, representing 1.55% of the outstanding common stock.
• Mr. Lichti is the Manager of Northstrive Fund II LP, and the filing indicates a passive investment under Rule 13d-1(c).
• The ownership percentages are calculated based on 708,533 shares of Bluejay Diagnostics, Inc. common stock outstanding as of January 29, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant beneficial ownership stake by a named individual and an associated fund can be interpreted as a vote of confidence in Bluejay Diagnostics, Inc.

Positives

• A new significant shareholder, Braeden Lichti, has acquired a 5.01% stake in Bluejay Diagnostics, Inc., potentially signaling confidence in the company's future.
• Northstrive Fund II LP, managed by Mr. Lichti, also holds a 1.55% stake, indicating institutional interest.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a 5.01% stake by an individual investor, especially one managing an investment fund, often signals a belief in the company's undervaluation or future growth potential. While not an activist stake, it represents a significant vote of confidence in Bluejay Diagnostics, Inc. within the diagnostics industry.

Comparison to Industry Standards

• A 5% beneficial ownership threshold is a key reporting benchmark in the U.S. market, triggering Schedule 13G or 13D filings. This level of ownership is substantial for an individual investor like Braeden Lichti, indicating a significant personal commitment to Bluejay Diagnostics, Inc.
• Compared to typical institutional holdings, a 5.01% stake by an individual, even one associated with a fund, is notable and suggests a high conviction investment, rather than a diversified portfolio allocation.

Stakeholder Impact

• Shareholders may view the acquisition of a significant stake by Braeden Lichti and Northstrive Fund II LP as a positive signal, potentially increasing investor confidence and demand for Bluejay Diagnostics, Inc. shares.

Key Dates

Recommendation

The disclosure of a 5.01% beneficial ownership stake by Braeden Lichti and Northstrive Fund II LP in Bluejay Diagnostics, Inc. is a positive indicator of investor confidence. However, without additional information on the company's financial performance, strategic direction, or market valuation, a 'hold' recommendation is prudent. This filing primarily signals a significant investor's belief in the company, but does not provide new operational data to justify a more aggressive stance.

Keywords

Bluejay Diagnostics, BJDX, Braeden Lichti, Northstrive Fund II LP, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Passive Investment